795 related articles for article (PubMed ID: 19565516)
21. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
22. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
Salobir B; Sabovic M; Zupan IP; Ponikvar JB
Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
[TBL] [Abstract][Full Text] [Related]
23. Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Li F; Zhang G; Zhao W
Chin Med J (Engl); 2003 Mar; 116(3):475-7. PubMed ID: 12781064
[TBL] [Abstract][Full Text] [Related]
24. Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach.
Lefranc D; Launay D; Dubucquoi S; de Seze J; Dussart P; Vermersch M; Hachulla E; Hatron PY; Vermersch P; Mouthon L; Prin L
Arthritis Rheum; 2007 Oct; 56(10):3420-32. PubMed ID: 17907141
[TBL] [Abstract][Full Text] [Related]
25. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes.
Kozora E; Arciniegas DB; Filley CM; West SG; Brown M; Miller D; Grimm A; Devore MD; Wingrove C; Zhang L
Arthritis Rheum; 2008 Nov; 59(11):1639-46. PubMed ID: 18975359
[TBL] [Abstract][Full Text] [Related]
26. Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus.
Fragoso-Loyo H; Atisha-Fregoso Y; Nuñez-Alvarez CA; Llorente L
Lupus; 2016 Apr; 25(4):364-9. PubMed ID: 26466614
[TBL] [Abstract][Full Text] [Related]
27. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus.
Yoshio T; Okamoto H; Kurasawa K; Dei Y; Hirohata S; Minota S
Lupus; 2016 Aug; 25(9):997-1003. PubMed ID: 26846690
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
29. Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus.
Ikenouchi-Sugita A; Yoshimura R; Okamoto T; Umene-Nakano W; Ueda N; Hori H; Katsuki A; Saito K; Tanaka Y; Nakamura J
World J Biol Psychiatry; 2010 Mar; 11(2):121-8. PubMed ID: 20109107
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
31. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study.
Ainiala H; Dastidar P; Loukkola J; Lehtimäki T; Korpela M; Peltola J; Hietaharju A
Scand J Rheumatol; 2005; 34(5):376-82. PubMed ID: 16234185
[TBL] [Abstract][Full Text] [Related]
32. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.
Sibbitt WL; Brandt JR; Johnson CR; Maldonado ME; Patel SR; Ford CC; Bankhurst AD; Brooks WM
J Rheumatol; 2002 Jul; 29(7):1536-42. PubMed ID: 12136916
[TBL] [Abstract][Full Text] [Related]
33. Antibodies in patients with neuropsychiatric systemic lupus erythematosus.
Kimura A; Kanoh Y; Sakurai T; Koumura A; Yamada M; Hayashi Y; Tanaka Y; Hozumi I; Takemura M; Seishima M; Inuzuka T
Neurology; 2010 Apr; 74(17):1372-9. PubMed ID: 20421581
[TBL] [Abstract][Full Text] [Related]
34. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles.
Jönsen A; Bengtsson AA; Nived O; Ryberg B; Truedsson L; Rönnblom L; Alm GV; Sturfelt G
Lupus; 2003; 12(11):846-50. PubMed ID: 14667101
[TBL] [Abstract][Full Text] [Related]
35. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
36. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
37. Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularisation.
Pärsson H; Holmberg A; Siegbahn A; Bergqvist D
Eur J Vasc Endovasc Surg; 2004 Feb; 27(2):186-92. PubMed ID: 14718902
[TBL] [Abstract][Full Text] [Related]
38. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.
Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E
Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397
[TBL] [Abstract][Full Text] [Related]
39. [Characteristic manifestations of neuropsychiatric systemic lupus erythematosus].
Liu Z; Chen L; Cui LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):509-12. PubMed ID: 16178450
[TBL] [Abstract][Full Text] [Related]
40. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
